Financial Contrast: Scholar Rock (NASDAQ:SRRK) versus Genmab A/S (OTCMKTS:GNMSF)

Scholar Rock (NASDAQ:SRRK) and Genmab A/S (OTCMKTS:GNMSF) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Volatility & Risk

Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Valuation & Earnings

This table compares Scholar Rock and Genmab A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94 million	($3.45)	-16.46
Genmab A/S	$3.72 billion	5.59	$963.00 million	$12.75	26.51

Genmab A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Scholar Rock and Genmab A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1	0	11	4	3.12
Genmab A/S	0	0	0	0	0.00

Scholar Rock currently has a consensus price target of $58.77, indicating a potential upside of 3.47%. Given Scholar Rock’s stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Genmab A/S.

Profitability

This table compares Scholar Rock and Genmab A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Genmab A/S	19.08%	14.89%	7.73%

Insider and Institutional Ownership

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Genmab A/S beats Scholar Rock on 8 of the 14 factors compared between the two stocks.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.